Insights

The COVID-19 pandemic has brought virtual clinical trial enablement into focus. A spectrum of technologies transformative to traditional trial management, we present areas of growth in a broadening clinical research vendor landscape flush with investor activity that is rapidly being shaped by regulatory and legislative activity.

In order for strong financial recovery to occur, it needs to begin now, even as we are still in the midst of the pandemic. Hospitals cannot rely solely on governmental intervention. As both the duration of the pandemic and what life after it will look like are still unclear, it’s even more important to initiate programs to accelerate cash, reduce costs, and reduce debt. In this white paper, Marwood explores strategies that will enable hospitals emerging from the clutches of the pandemic to not only recover quickly, but also thrive.

Millions of Americans have lost their jobs as a result of COVID-19, often losing their health insurance simultaneously. When individuals lose their employer-based minimum essential coverage, they qualify for a special enrollment period (SEP), and can enroll in individual market plans through the ACA exchanges. In this white paper, Marwood Group explores the impact of the dramatic increase in unemployment on exchange plan enrollment, with a particular focus on state-run exchanges that have established SEPs in response to the pandemic-driven economic downturn.

The COVID-19 pandemic has reshaped each stage of the life science development and investment process. In Part 1 and Part 2 of a three-part series, Marwood addressed the life science venture capital and private equity space, as well as the state of the crossover investor and IPO landscape. In this final installment, Marwood examines the state of the mergers & acquisition (M&A) landscape for end acquirers – manufacturers in the life sciences sector – across the pharmaceutical, diagnostic, and medical device space.